Presentations by Event

Resistance to Sulbactam-Durlobactam in Clinical Isolates of Acinetobacter baumannii is Rare and Maps to PBP3

Moussa S, Shapiro AB, McLeod SM and Miller AA (Acinetobacter 2019)

Program(s): durlobactam (etx2514)

Discovery of a Novel Series of Penicillin-binding Protein 3 Inhibitors to Treat Pseudomonas aeruginosa Infections: Rational Design of Biochemical Potency and Bacterial Permeation

Durand-Reville T, Wu X, Guler S, Zhang J, Comita-Prevoir J, Sylvester M, Romero J, Velez-Vega C, Wu F, Iyer R, Shapiro A, Moussa S, Carter N, Chen A, McLeod S, O'Donnell J, Miller A and Tommasi R (ASM ESCMID 2019)

The Novel β-lactamase Inhibitor ETX1317 Restores the Activity of Cefpodoxime Against Drug-Resistant Enterobacteriaceae

McLeod S, Carter N, Moussa S, Mueller J, Tommasi R and Miller A (Microbe 2019)

Program(s): etx0282

Cefpodoxime-ETX1317 Susceptibility is Unaffected by Ceftazidime-Avibactam Resistance Mutations V240G, D179Y and D179Y/T243M in KPC-3 β-Lactamase

Shapiro AB, Moussa SH, Carter NM, Gao N and Miller AA (Microbe 2019)

Program(s): etx0282

Novel Therapies Targeting Drug-Resistant Gonorrhea

Mueller JP (Microbe 2019)

Program(s): zoliflodacin (etx0914)

The Novel β-lactamase Inhibitor ETX2514 Restores Sulbactam Activity against Recent, Globally Diverse Clinical Isolates of Acinetobacter baumannii calcoaceticus Complex Isolates

McLeod S, Huband M, Edah Y, Tommasi R and Miller A (Microbe 2019)

Program(s): durlobactam (etx2514)

Scientific Overview of Entasis Pipeline

Tommasi R (Microbe 2019)

Pharmacokinetics/Pharmacodynamics and Phase 3 Dose Projection For the Novel β-lactamase Inhibitor ETX2514 in Combination with Sulbactam Against Acinetobacter baumannii calcoaceticus Complex (ABC)

O'Donnell J (Microbe 2019)

Program(s): durlobactam (etx2514)